Cure8 research brief
This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is still inconsistent and needs higher‑quality trials.
Patients with UC may see this as a potential adjunctive, microbiome‑related therapy under investigation.
Adult patients with ulcerative colitis; caregivers and parents of pediatric IBD patients (given inconsistent pediatric data); gastroenterologists and clinicians managing UC; researchers studying microbiome‑based or adjunctive IBD therapies.
This systematic review summarizes clinical and preclinical studies of sodium butyrate (a short‑chain fatty acid produced by gut bacteria) given orally or rectally for ulcerative colitis (UC).
The authors screened trials and animal studies and report that oral, especially microencapsulated, sodium butyrate showed encouraging adjunctive effects on clinical remission, quality of life, disease activity and inflammatory markers in adults with UC, while rectal enemas had mixed clinical results despite local biological effects.
The review includes 10 clinical trials, one prospective observational study, and 11 animal studies. Preclinical work consistently found reduced intestinal inflammation, improved epithelial barrier integrity, modulation of oxidative stress, shifts in gut microbiota, and effects on pathways such as PI3K/AKT/mTOR, WNT/ERK, ERK/STAT3, autophagy and ferroptosis.
The authors conclude the evidence is promising but heterogeneous and call for larger, well‑designed randomized trials using standardized formulations and protocols before routine clinical use. Practical takeaways: this is an evidence synthesis suggesting potential benefit of sodium butyrate as an adjunctive therapy for adult UC, but it is not definitive.
Formulation (oral microencapsulation) and study quality varied across trials, and pediatric data were inconsistent.
The article is a systematic review (abstract level synthesis) published in a peer‑reviewed journal and registered in PROSPERO. The authors note heterogeneity in study designs, formulations, and outcomes; they recommend larger randomized controlled trials with standardized sodium butyrate products before routine clinical adoption.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: University of Medicine and Pharmacy
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...
Diet is a modifiable factor many people with IBD try to use to feel better. This review summarizes current evidence that a Mediterranean-style eating pattern may help quality of life and is linked to lower inflammation...
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
